A cross-over, pharmacokinetic pilot study (single oral dose) in humanscompared a typical ubiquinol preparation to ubiquinol in the VESIsorb® delivery system and demonstrated a 696% increase in peak blood levels (Cmax) and a 485% increase in relative bioavailability (AUC(0-24 hr)).
A clinical study of CoQ10 with the VESIsorb® delivery system indicates a peak absorption of 16.97% compared to reported peak absorption of CoQ10 powder, an oil dispersion and a lipid solution which were at 2.15%, 3.34% and 5.44% respectively.
The VESIsorb® delivery system enhanced CoQ10 bioavailability by 622% compared to oil-based CoQ10 and 499% compared to solubilized CoQ10.
Ubiquinol is the active antioxidant form of CoQ10, the preferred form for individuals over 40 or those experiencing increased oxidative stress.
Caplique® Capsule is a registered trademark used by Pure Encapsulations under license. Each Caplique® Capsule is preserved with a nitrogen bubble, which may give the appearance of the capsule not being full. Contents may appear cloudy or thick and may settle or separate.
VESISORB® is a registered trademark of Source One Global Partners.
Kaneka QH is a registered trademark of Kaneka corporation.
These statements have not been evaluated by the Food and Drug Administration (FDA). These products are not meant to diagnose, treat or cure any disease or medical condition. Please consult your doctor before starting any exercise or nutritional supplement program or before using these or any product during pregnancy or if you have a serious condition.